Mccarter Private Wealth Services LLC Lowers Stake in Thermo Fisher Scientific Inc. $TMO

Mccarter Private Wealth Services LLC lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,533 shares of the medical research company’s stock after selling 170 shares during the period. Thermo Fisher Scientific accounts for 2.8% of Mccarter Private Wealth Services LLC’s investment portfolio, making the stock its 9th largest position. Mccarter Private Wealth Services LLC’s holdings in Thermo Fisher Scientific were worth $4,246,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. D.B. Root & Company LLC lifted its position in shares of Thermo Fisher Scientific by 21.7% during the 1st quarter. D.B. Root & Company LLC now owns 1,120 shares of the medical research company’s stock valued at $557,000 after buying an additional 200 shares during the last quarter. 1832 Asset Management L.P. lifted its position in shares of Thermo Fisher Scientific by 45.1% during the 1st quarter. 1832 Asset Management L.P. now owns 788,775 shares of the medical research company’s stock valued at $392,494,000 after buying an additional 245,212 shares during the last quarter. Compound Planning Inc. raised its stake in shares of Thermo Fisher Scientific by 52.4% during the 1st quarter. Compound Planning Inc. now owns 3,992 shares of the medical research company’s stock valued at $1,987,000 after purchasing an additional 1,373 shares during the period. Bragg Financial Advisors Inc lifted its holdings in Thermo Fisher Scientific by 4.2% during the 1st quarter. Bragg Financial Advisors Inc now owns 13,498 shares of the medical research company’s stock worth $6,717,000 after purchasing an additional 538 shares in the last quarter. Finally, Norinchukin Bank The lifted its holdings in Thermo Fisher Scientific by 15.0% during the 1st quarter. Norinchukin Bank The now owns 19,430 shares of the medical research company’s stock worth $9,668,000 after purchasing an additional 2,531 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on TMO shares. Wells Fargo & Company dropped their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a report on Thursday, July 24th. Barclays raised their price target on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an “equal weight” rating in a report on Thursday, July 24th. William Blair started coverage on Thermo Fisher Scientific in a report on Monday. They issued an “outperform” rating on the stock. Raymond James Financial reiterated an “outperform” rating and set a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Royal Bank Of Canada reduced their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a research report on Thursday, April 24th. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $593.00.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total value of $4,518,200.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares of the company’s stock, valued at approximately $52,037,916.68. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 18,896 shares of company stock valued at $8,593,838. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Price Performance

TMO opened at $483.4280 on Friday. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The stock’s 50 day simple moving average is $441.06 and its 200 day simple moving average is $458.02. The firm has a market cap of $182.55 billion, a price-to-earnings ratio of 27.96, a PEG ratio of 2.64 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion during the quarter, compared to analysts’ expectations of $10.68 billion. During the same quarter last year, the business posted $5.37 EPS. The business’s revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.